Viking Therapeutics Inc Stock
€47.27
Your prediction
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | 0.660% | -1.033% | -9.191% | 235.934% | 168.401% | 778.839% | - |
| Ardelyx Inc. | 0.220% | -19.513% | -22.472% | 60.393% | -15.363% | -26.985% | - |
| Evolus Inc | 2.620% | -1.546% | -16.957% | 48.062% | 5.525% | -9.048% | - |
| Brainstorm Cell | -4.330% | -7.439% | -28.031% | -82.514% | 43.142% | -89.565% | -90.957% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.
1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.
2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.
News
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's
The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping